At the Study of Liver Diseases 1998 Annual Meeting in Chicago, November 6 - 10, some of the world's top biomedical researchers unveiled studies of drug therapies that are offering new hope in the fight against Hepatitis.
Research that could point the way to more effective gene therapies for liver and other diseases was made public at The American Association for the Study of Liver Diseases.
A study presented at The American Association for the Study of Liver Diseases meeting predicts that the US could face a daunting health care burden from Hepatitis C virus infection over the next decade.
Researchers at the American Association for the Study of Liver Diseases Annual Meeting discussed disturbing new findings indicating that interferon, the most commonly used drug against chronic Hepatitis C, is much less effective for African Americans than it is for other racial and ethnic groups.
The nation's liver disease researchers will present breakthrough therapies and technologies in liver disease November 8-10 at the 49th Annual Meeting of the American Association for the Study of Liver Diseases.
The nation's leading transplant surgeons and researchers will present breakthrough therapies and technologies
New Drugs, New Approaches to Transplant Technologies Presented at Annual Meeting
New Islet Cell TRansplantation Centers Boost Research on Diabetes Cure
At the AST Annual Scientific Meeting, researchers from Children's Hospital of Pittsburgh and St. Christopher's Hospital for Children, will discuss studies which that show that splitting livers from donors--transplanting into two recipients--can be an effective way to meet the need for donated organs.
Organ donations have increased fivefold as families are more willing to consider organ donation. At the American Society of Transplantation Annual Scientific Meeting in Chicagoa a discussion of data on public attitudes towards donation.
Independent, scientific and medical expert listed below by the American Association of Liver Diseases provide commentary for reporters and medical advice for the public
A new study shows that important increases in recovery from chronic hepatitis B are obtained by prolonging the therapy up to four months, according to a study in the July issue of HEPATOLOGY.
The results of the first international study of quality of life outcomes in hepatitis C conducted by the International Hepatitis Interventional Therapy Group are reported by Ware and his colleagues in the August issue of HEPATOLOGY, the monthly peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).
The nation's leading biomedical researchers will present breakthrough therapies and technologies in liver disease November 5 through November 9 at the 50th Annual Meeting of the American Association for the Study of Liver Diseases.
A new study released for the first time at the American Association for the Study of Liver Diseases 1999 annual meeting suggests that the United States may soon be seeing an increase in carcinoma cases related to hepatitis C virus infection.
1- impact of race to hepatitis treatment, 2- transmission of hepatitis from mother to infant, and 3- missed diagnoses of liver disease described at the American Association for the Study of Liver Diseases Annual Meeting in Dallas Nov 5-9.
Genetic factors play a role in the development of advanced alcoholic liver disease (ALD) in heavy drinkers, suggests a new study released at the American Association for the Study of Liver Diseases 2000 Annual Meeting in Dallas, October 29 -- 31.
This tip sheet highlights only a few of the hundreds of abstracts being presented by members of the American Association of the Study of Liver Diseases at Digestive Disease Week, the largest international meeting of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found that increased utilization of split liver transplantation (sharing a donor liver between one pediatric and one adult patient) could decrease the number of children who die awaiting liver transplantation without decreasing liver transplantation access for adult patients.
Nonalcoholic fatty liver disease is associated with significantly higher risk of subsequent cardiovascular events in women, but not in men, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
Research presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – shows people in treatment for opioid substance abuse significantly lowered their non‐prescribed opioid use after testing positive for hepatitis C virus.
Health care costs for privately insured patients with alcoholic cirrhosis are nearly twice that of non‐alcoholic cirrhosis patients in the United States, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
Serum metabolites associated with nonalcoholic fatty liver disease may be heritable, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found that eradication of the hepatitis C virus induced by direct‐acting antiviral medications is associated with a 71 percent reduction in the risk of liver cancer.
Herbal and dietary supplement mislabeling is common and should be evaluated as a potential cause for liver damage, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
A new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that liver cirrhosis mortality is greater than that of five major cancers, implying the development of appropriate interventions to treat or prevent liver cirrhosis must be prioritized.
A new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that the overall number of pregnancies in women with chronic liver disease or following liver transplantation has risen over the past 30 years. In addition, the proportion of full‐term pregnancies has increased significantly over that time period, and most women had favorable pregnancy outcomes.
Use of liver organs from selected hepatitis C positive donors should be considered due to modest risk of hepatitis C transmission and the availability of safe and effective direct‐acting antiviral therapies, according to research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases.
A new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer.
A new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer.
a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the management of hepatitis C (HCV) — has updated several sections of the website to reflect new testing and management recommendations for pregnant women, people who inject drugs, men who have sex with men and people who are incarcerated.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that weight-loss surgery prior to liver transplantation is superior to medical weight loss approaches at achieving sustained weight loss, as well as significantly lowering risk of metabolic complications after transplant.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that patients treated with immune checkpoint inhibitors rarely develop severe liver toxicity, but the majority of those who do permanently stop this cancer treatment. None of the patients developed liver failure as a result of this treatment.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hospitalizations and death are increasing among Medicare recipients with hepatocellular carcinoma, mainly due to co-existing alcoholic liver disease, hepatitis C virus infection (commonly called HCV) and nonalcoholic fatty liver disease (commonly called NAFLD).
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that people who inject drugs who are infected with the hepatitis C virus have high rates of hepatitis C treatment adherence (completion of their treatment), and sustained virologic response. Based on these findings, researchers conclude these patients should be included in HCV treatment programs.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that African-American patients on waitlists for liver transplantation, despite severe disease and high scores for prioritization, persistently face significant disparities and delays in referral.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found the combination of glecaprevir and pibrentasvir is highly effective and well tolerated in patients with chronic hepatitis C virus (commonly called HCV) genotype-1 infections who have prior treatment experience with sofosbuvir/NS5A inhibitor.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by The American Association for the Study of Liver Diseases – found that universal screening of pregnant women at risk for hepatitis C virus (commonly called HCV) infection is a more efficient and cost-effective diagnostic approach than risk-based screening.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that rates of malignancy occurring outside of the liver were higher in adults with nonalcoholic fatty liver disease than among adults across most types of cancers.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that using normothermic machine perfusion to preserve steatotic livers leads to altered lipid structure and metabolism and may result in more successful transplantation of these organs.
SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that more than half of pediatric liver transplant recipients are under-immunized at the time of their transplant and are at increased risk for vaccine-preventable infections.
SAN FRANCISCO – Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that taking a regular aspirin is associated with a dose-dependent reduction in the risk of hepatocellular carcinoma, one of the most common liver cancers. The cancer risk reduction is apparent after at least five years of aspirin use, the study showed.
Hepatology Communications’ newest team member has hit the ground running by adding visual abstracts to the publication and working on other new ways to increase the visibility and readership for the journal.
The American Association for the Study of Liver Diseases Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.42 million in Research and Career Development Awards granted to 29 researchers and clinicians to conduct innovative liver disease research and seek advanced hepatology training.
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that a machine-learning tool could successfully predict the risk of having non-alcoholic steatohepatitis (NASH) among patients with co-existing diseases.
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that combination therapy with direct-acting antivirals (DAAs) and ezetimibe
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that obese individuals with nonalcoholic fatty liver disease (NAFLD) were less likely to achieve a medically recommended five percent loss of body weight at three months
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus - with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right